4-溴-3-甲基苯硫醇 | 14395-52-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯硫酚类
• 中文名称: 4-溴-3-甲基苯硫醇
• 英文名称: 3-methyl-4-bromothiophenol
• 英文别名: 4-Brom-3-methyl-thiophenol；4-Bromo-3-methyl-benzenethiol；4-bromo-3-methylbenzenethiol
• CAS: 14395-52-9
• 化学式: C₇H₇BrS
• 分子量: 203.103
• InChiKey: LZJWLHDEWPQTPL-UHFFFAOYSA-N

物化性质

• 沸点：
  258-262 °C
• 密度：
  1.1398 g/cm3(Temp: 26 °C)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  1
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2930909090

反应信息

• 作为反应物：
  描述：

  4-溴-3-甲基苯硫醇 在 sodium ethanolate 作用下， 以 甲醇 、 四氯化碳 、 乙醇 、 乙腈 为溶剂， 反应 18.25h， 生成 4-(4-Bromo-3-methyl-phenylsulfanyl)-pyridine
  参考文献：
  名称：

  N–N连锁杂环的合成应用。第12部分。通过硫代烷醇盐对N-（4-氧代吡啶-1-基）吡啶鎓盐的区域专一性攻击制备4-烷硫基吡啶和4-芳硫基吡啶

  摘要：

  硫醇离子对N-（4-氧代吡啶-1-基）吡啶鎓盐（2）-（7）呈区域特异性添加，仅产生1,4-二氢吡啶加合物（8）-（13）即可获得优异的优良收率吡啶酮部分是否带有取代基以立体屏蔽吡啶鎓环的2位和6位。据信该添加是热力学控制的。在自由基条件下或通过热解分解二氢加合物，尽管2-甲基加合物（9）反应失败，但吡啶4-基硫醚（14）和（16）的收率很高。还描述了6-甲基-4-氧杂吡喃-2-羧酸的改进的合成。

  DOI：

  10.1039/p19810001585
• 作为产物：
  描述：

  2-(3-甲基苯基)硫基乙酸 在 硫酸 、 双氧水 、 溴 作用下， 以 溶剂黄146 为溶剂， 生成 4-溴-3-甲基苯硫醇
  参考文献：
  名称：

  Electrophilic Substitution of the Benzenethiols. I. Halobenzene- and Halotoluenethiols¹

  摘要：

  DOI：

  10.1021/jo01059a081

文献信息

• Substituted benzoxazin-2-ones and pharmaceutical compositions containing
  申请人：Dr. Karl Thomae GmbH

  公开号：US04518597A1

  公开（公告）日：1985-05-21

  This invention is directed to novel benzoxazin-2-ones of the formula ##STR1## wherein A is a sulfur atom or an SO, SO.sub.2, R--N.dbd.S, or R--N.dbd.SO.sub.2 group where R is a hydrogen atom or an acyl group; D is an alkylene group; R.sub.1 is an alkyl, phenylalkyl, cycloalkyl, or phenyl group; R.sub.4 is a hydrogen atom or an alkyl group; R.sub.5 is a hydrogen or halogen atom or a nitro or alkyl group; and R.sub.6 is a hydrogen or halogen atom or an alkyl group, having valuable pharmacological properties, particularly an antithrombotic activity. The compounds of Formula I may be prepared by the methods used for analogous compounds.

  这项发明涉及一种新型苯并噁唑啉-2-酮，其化学式为##STR1##其中A是硫原子或SO、SO.sub.2、R--N.dbd.S或R--N.dbd.SO.sub.2基团，其中R是氢原子或酰基；D是烷基基团；R.sub.1是烷基、苯基烷基、环烷基或苯基基团；R.sub.4是氢原子或烷基基团；R.sub.5是氢原子或卤素原子或硝基或烷基基团；R.sub.6是氢原子或卤素原子或烷基基团，具有有价值的药理特性，特别是抗血栓活性。式I的化合物可以通过用于类似化合物的方法制备。
• [EN] ROR GAMMA (RORY) MODULATORS<br/>[FR] MODULATEURS DU ROR GAMMA (RORY)
  申请人：LEAD PHARMA CEL MODELS IP B V

  公开号：WO2015082533A1

  公开（公告）日：2015-06-11

  The present invention relates to compounds according to Formula I: Wherein: A11 - A14 are N or CR11, CR12, CR13, CR14, respectively, with the proviso that no more than two of the four positions A can be simultaneously N; R1 is C(1-6)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1 -3)alkyl, (di)C(1-6)alkylamino, (di)C(3-6)cycloalkylamino or (di)(C(3-6)cycloalkylC(1 -3)alkyl)amino, with all carbon atoms of alkyl groups optionally substituted with one or more F and all carbon atoms of cycloalkyl groups optionally substituted with one or more F or methyl; R2 and R3 are independently H, F, methyl, ethyl, hydroxy, methoxy or R2 and R3 together is carbonyl, all alkyl groups, if present, optionally being substituted with one or more F; R4 is H or C(1-6)alkyl; R5 is H, hydroxyethyl, methoxyethyl, C(1-6)alkyl, C(6-10)aryl, C(6-10)arylC(1-3)alkyl, C(1 -9)heteroaryl, C(1-9)heteroarylC(1-3)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1 -3)alkyl, C(2-5)heterocycloalkyl or C(2-5)heterocycloalkylC(1-3)alkyl, all groups optionally substituted with one or more F, CI, C(1-2)alkyl, C(1-2)alkoxy or cyano; the sulfonyl group with R1 is represented by one of R7, R8 or R9; the remaining R6-RH are independently H, halogen, C(1-3)alkoxy, (di)C(1-3)alkylamino or C(1-6)alkyl, all of the alkyl groups optionally being substituted with one or more F; and Ri5 and Ri6 are independently H, C(1-6)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1-3)alkyl, C(6-10)aryl, C(6-10)arylC(1-3)alkyl, C(1-9)heteroaryl, C(1-9)heteroarylC(1-3)alkyl, C(2-5)heterocycloalkyl or C(2-5)heterocycloalkylC(1-3)alkyl, all groups optionally substituted with one or more F, CI, C(1-2)alkyl, C(1-2)alkoxy or cyano. The compounds can be used as inhibitors of RORy and are useful for the treatment of RORy mediated diseases.

  本发明涉及符合以下式I的化合物：其中：A11 - A14分别为N或CR11，CR12，CR13，CR14，但四个位置A中不超过两个可以同时为N；R1为C(1-6)烷基，C(3-6)环烷基，C(3-6)环烷基C(1-3)烷基，(双)C(1-6)烷基氨基，(双)C(3-6)环烷基氨基或(双)(C(3-6)环烷基C(1-3)烷基)氨基，烷基族的所有碳原子可选择性地被一个或多个F取代，环烷基族的所有碳原子可选择性地被一个或多个F或甲基取代；R2和R3独立地为H，F，甲基，乙基，羟基，甲氧基或R2和R3一起为羰基，所有烷基族（如果存在）可选择性地被一个或多个F取代；R4为H或C(1-6)烷基；R5为H，羟乙基，甲氧乙基，C(1-6)烷基，C(6-10)芳基，C(6-10)芳基C(1-3)烷基，C(1-9)杂环芳基，C(1-9)杂环芳基C(1-3)烷基，C(3-6)环烷基，C(3-6)环烷基C(1-3)烷基，C(2-5)杂环烷基或C(2-5)杂环烷基C(1-3)烷基，所有基团可选择性地被一个或多个F，CI，C(1-2)烷基，C(1-2)烷氧基或氰取代；与R1相连的磺酰基由R7，R8或R9之一表示；其余的R6-RH独立地为H，卤素，C(1-3)烷氧基，(双)C(1-3)烷基氨基或C(1-6)烷基，所有烷基族可选择性地被一个或多个F取代；Ri5和Ri6独立地为H，C(1-6)烷基，C(3-6)环烷基，C(3-6)环烷基C(1-3)烷基，C(6-10)芳基，C(6-10)芳基C(1-3)烷基，C(1-9)杂环芳基，C(1-9)杂环芳基C(1-3)烷基，C(2-5)杂环烷基或C(2-5)杂环烷基C(1-3)烷基，所有基团可选择性地被一个或多个F，CI，C(1-2)烷基，C(1-2)烷氧基或氰取代。这些化合物可用作RORγ的抑制剂，并且对于治疗RORγ介导的疾病是有用的。
• Thio derivatives of N-trifluoroacetyl-N-phosphonomethylglycine
  申请人：Monsanto Company

  公开号：US04175946A1

  公开（公告）日：1979-11-27

  This disclosure relates to thio derivatives of N-trifluoroacetyl-N-phosphonomethylglycine esters, to herbicidal compositions containing same and to the herbicidal use thereof. The thio derivatives of N-trifluoroacetyl-N-phosphonomethylglycine esters are useful as herbicides.

  这项披露涉及N-三氟乙酰-N-磷酸甲基甘氨酸酯的硫代衍生物，含有相同成分的除草剂组合物，以及其除草用途。N-三氟乙酰-N-磷酸甲基甘氨酸酯的硫代衍生物可用作除草剂。
• Disubstituted acetylenes bearing heteroaromatic and heterobicyclic
  申请人：Allergan

  公开号：US05602130A1

  公开（公告）日：1997-02-11

  Retinoid-like activity is exhibited by compounds of the formula ##STR1## where X is S, O, or NR' where R' is hydrogen or lower alkyl; R is hydrogen or lower alkyl; A is pyridyl, thienyl, furyl, pyridazinyl, pyrimidinyl or pyrazinyl; n is 0-4; and B is H, --COOH or a pharmaceutically acceptable salt, ester or amide thereof, --CH.sub.2 OH or an ether or ester derivative, or --CHO or an acetal derivative, or --COR.sub.1 or a ketal derivative where R.sub.1 is --(CH.sub.2).sub.m CH.sub.3 where m is 0-4, or a pharmaceutically acceptable salt thereof.

  化合物具有类似视黄醇的活性，其化学式为##STR1##其中X为S、O或NR'，R'为氢或较低的烷基；R为氢或较低的烷基；A为吡啶基、噻吩基、呋喃基、吡啶并嗪基、嘧啶基或吡嗪基；n为0-4；B为H、--COOH或其药学上可接受的盐、酯或酰胺，--CH.sub.2 OH或醚或酯衍生物，或--CHO或缩醛衍生物，或--COR.sub.1或缩酮衍生物，其中R.sub.1为--(CH.sub.2).sub.m CH.sub.3，m为0-4，或其药学上可接受的盐。
• Hydroxy pyrimido compounds
  申请人：E. R. Squibb & Sons, Inc.

  公开号：US04062846A1

  公开（公告）日：1977-12-13

  Compounds of the formula ##STR1## and tautomers thereof exhibit central nervous system stimulating properties and act as muscle relaxants.

  式##STR1##的化合物及其互变异构体表现出中枢神经系统刺激特性，并作为肌肉松弛剂。